Inhibition of IKK-controlled NF-κB activation provides a rational clinical strategy to overcome acquired drug chemoresistance in cancer via modulation of balance in cell death/proliferation and thus convert inflammation-induced cancer progression/resistance to cancer regression. The gene discussed is NFKB1; the disease is cancer.